Metabolomics and risk of Parkinson's Disease

代谢组学和帕金森病的风险

基本信息

批准号：
9313961
负责人：
ALBERTO ASCHERIO
金额：
$ 56.31万
依托单位：
HARVARD SCHOOL OF PUBLIC HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9313961
关键词：
Affect Age Alanine American Archives Biological Markers Blood Blood specimen Branched-Chain Amino Acids Caffeine Cancer Prevention Study II Choline Chronic Chronic Disease Clinical Coffee Cohort Studies Confounding Factors (Epidemiology)Consumption Controlled Study Creatine Cross-Sectional Studies Data Data Collection Diabetes Mellitus Diagnosis Diagnostic Diet Disease Disease Progression Early Diagnosis Early identification Etiology Event Failure Follow-Up Studies Functional disorder Funding Glutamates Goals Health Professional Incidence Individual Institutes Insulin Resistance Investigation Life Style Machine Learning Measures Mediating Medical Medical History Metabolic Metabolic Pathway Methods Motor National Institute of Neurological Disorders and Stroke Nature Nerve Degeneration Neurodegenerative Disorders Nurses&apos Health Study Parkinson Disease Participant Patients Persons Phase Physical activity Plasma Population Progressive Disease Research Resources Risk Risk Factors Sampling Smoking Specificity Techniques Therapeutic Time United States United States National Institutes of Health Update Urate Validation Women&apos s Health Nursing Work acylcarnitine aging population base brain cell cancer prevention case control cigarette smoking clinical Diagnosis cohort design diabetes risk disability disorder risk follow-up gender difference insight interest men metabolic profile metabolome metabolomics mitochondrial dysfunction motor symptom neuron loss novel novel strategies nutrition peripheral blood pre-clinical prospective public health relevance sex specific biomarkers tool

项目摘要

DESCRIPTION (provided by applicant): Parkinson disease (PD) is the second most common neurodegenerative disease in the United States and affects over one million Americans; this number is growing due to population aging. Current treatments do not prevent the disease progression that ultimately results in severe disability. There is thus a compelling need to develop neuroprotective treatments. Because at the time of the clinical diagnosis of PD there is already substantial neuronal loss, such treatments should ideally be initiated earlier. Aims of the proposed investigation are to implement and validate a novel metabolomic approach for the identification of early changes in peripheral blood of individuals with preclinical or premotor PD. The metabolomic results will be integrated with detailed and validated information on risk factors for PD, which has been collected prospectively and periodically updated. We expect by this means to identify new clues to the etiology of PD and to identify a metabolomic signature of PD that could contribute to an early diagnosis. To achieve these goals, we will take advantage of data and blood samples collected from over 80,000 participants in three large ongoing cohorts, the Nurses' Health Study (NHS), the Health Professional Follow-up Study (HPFS), and the Cancer Prevention Study-II Nutrition, who have been followed for over 25 years for incident Parkinson disease. We expect to include a total of 805 incident cases of PD that will be matched to 805 controls, using a nested case-control design.

描述（由适用提供）：帕金森氏病（PD）是美国第二常见的神经退行性疾病，影响了100万美国人；由于人口衰老，这个数字正在增长。当前的治疗并不能阻止最终导致严重残疾的疾病进展。因此，迫切需要开发神经保护治疗。因为在PD临床诊断时，已经存在大量神经元丧失，因此理想情况下应早先开始这种治疗。目的拟议的研究是实施和验证一种新型代谢组方法，以鉴定临床前或前PD患者外周血的早期变化。代谢组结果将与有关PD风险因素的详细且经过验证的信息集成，该信息已被预期和定期更新。我们期望通过这种方式确定PD病因的新线索，并确定PD的代谢组签名，可能有助于早期诊断。为了实现这些目标，我们将利用从三个大型持续人群，护士健康研究（NHS），卫生专业后续研究（HPFS）（HPFS）和癌症预防研究-II研究-II营养中收集的数据和血液样本，他们在25年以上，以超过25年的帕克森病。我们预计将使用嵌套的情况对照设计包括805个PD事件案例，将与805个控件匹配。